136 results on '"Bercovich D"'
Search Results
2. THE MANY FACES OF GLUT1 DEFICIENCY - WE ALWAYS HAVE TO RETHINK ON OUR “OLD” PATIENTS: 006
- Author
-
Tzadok, M, Proper, K, Matot, I, Marcu, S, Nissenkorn, A, Anikster, Y, Menascu, S, Bercovich, D, and Ben-Zeev, B
- Published
- 2010
3. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations
- Author
-
Hershkovitz, D., Bercovich, D., Sprecher, E., and Lapidot, M.
- Published
- 2008
4. A Mutation Analysis of the Phenylalanine Hydroxylase (PAH) Gene in the Israeli Population
- Author
-
Bercovich, D., Elimelech, A., Yardeni, T., Korem, S., Zlotogora, J., Gal, N., Goldstein, N., Vilensky, B., Segev, R., Avraham, S., Loewenthal, R., Schwartz, G., and Anikster, Y.
- Published
- 2008
5. Unique activating mutations of JAK2 in the acute lymphoblastic leukaemias of Down syndrome: 163
- Author
-
Ganmore, I, Bercovich, D, Scott, L M, Wainreb, G, Cazzanigaz, G, Cario, G, Strehl, S, Binder, V, Kempski, H, Trka, J, Bielorei, B, Stark, B, Smith, O, Dastugue, N, Bourquin, J P, Biondi, A, Basso, G, Schrappe, M, Stanulla, M, Haas, O A, Mann, G, Borkhardt, A, Avigad, S, Ben-Tal, N, Green, A R, and Izraeli, S
- Published
- 2008
6. The CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal recessive non-syndromic mental retardation
- Author
-
Basel-Vanagaite, L, Attia, R, Yahav, M, Ferland, R J, Anteki, L, Walsh, C A, Olender, T, Straussberg, R, Magal, N, Taub, E, Drasinover, V, Alkelai, A, Bercovich, D, Rechavi, G, Simon, A J, and Shohat, M
- Published
- 2006
7. A novel heterozygous IGF-1 receptor mutation associated with hypoglycemia
- Author
-
Solomon-Zemler, R, primary, Basel-Vanagaite, L, additional, Steier, D, additional, Yakar, S, additional, Mel, E, additional, Phillip, M, additional, Bazak, L, additional, Bercovich, D, additional, Werner, H, additional, and de Vries, L, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Genetics studies of neuronal nicotinic acetylcholine receptors in patients with megacystis and intestinal pseudo-obstruction
- Author
-
Lev-Lehman, E., Lising, M., Bercovich, D., Xu, W., and Beaudet, A.L.
- Subjects
Human genetics -- Research ,Genetic disorders -- Research ,Gastrointestinal diseases -- Genetic aspects ,Biological sciences - Published
- 2001
9. Megacystic, Microcolon, Hypoperistalsis (MMIHS) and Pseudo-Obstruction syndromes: Searching for the human genes
- Author
-
Lev-Lehman, E., Bercovich, D., Xu, W., and Beaudet, A.L.
- Subjects
Genetic research -- Analysis ,Human genetics -- Research ,Genetic disorders -- Research ,Biological sciences - Published
- 2000
10. Denaturing High Performance Liquid Chromatography (DHPLC) used in the detection of mutations and polymorphisms in the UBE3A gene
- Author
-
Bercovich, D., LevLehman, E., and Beaudet, A.L
- Subjects
Genetic research -- Analysis ,Human genetics -- Research ,Gene mutations -- Research ,Biological sciences - Published
- 2000
11. Severe infantile male encephalopathy is a result of early post-zygoticWDR45somatic mutation
- Author
-
Spiegel, R., primary, Shalev, S., additional, Bercovich, D., additional, Rabinovich, D., additional, Khayat, M., additional, Shaag, A., additional, and Elpeleg, O., additional
- Published
- 2016
- Full Text
- View/download PDF
12. Case Study: A Human Pre-Natal Experiment in 1944—“Do No Harm”
- Author
-
Bercovich, D., primary, Shlush, K., additional, and Goodman, G., additional
- Published
- 2016
- Full Text
- View/download PDF
13. The Two-Brains Hypothesis: Towards a guide for brain–brain and brain–machine interfaces
- Author
-
Goodman, G., primary, Poznanski, R. R., additional, Cacha, L., additional, and Bercovich, D., additional
- Published
- 2015
- Full Text
- View/download PDF
14. Novel activating mutations lacking cysteine in type i cytokine receptors in acute lymphoblastic leukemia
- Author
-
Shochat, C, Tal, N, Gryshkova, V, Birger, Y, Bandapalli, O, Cazzaniga, G, Gershman, N, Kulozik, A, Biondi, A, Mansour, M, Twizere, J, Muckenthaler, M, Ben-Tal, N, Constantinescu, S, Bercovich, D, Izraeli, S, Bandapalli, OR, Kulozik, AE, Mansour, MR, Twizere, JC, Muckenthaler, MU, Constantinescu, SN, Shochat, C, Tal, N, Gryshkova, V, Birger, Y, Bandapalli, O, Cazzaniga, G, Gershman, N, Kulozik, A, Biondi, A, Mansour, M, Twizere, J, Muckenthaler, M, Ben-Tal, N, Constantinescu, S, Bercovich, D, Izraeli, S, Bandapalli, OR, Kulozik, AE, Mansour, MR, Twizere, JC, Muckenthaler, MU, and Constantinescu, SN
- Abstract
Gain-of-function somatic mutations introducing cysteines to either the extracellular or to the transmembrane domain (TMD) in interleukin-7 receptor a (IL7R) or cytokine receptor like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD closer to the cytosolic domain. Biochemical and functional assays showed that these are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells in vitro and are transforming in vivo. Protein fragment complementation assays suggest that despite the absence of cysteines, the mechanism of activation is through ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations suggest that the mutations stabilize the homodimeric conformation, positioning the cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous receptor activation independently of external signals. Hence, type I cytokine receptors may be activated in leukemia through 2 types of transmembrane somatic dimerizing mutations
- Published
- 2014
15. Unique activating mutations of JAK2 in the acute lymphoblastic leukaemias of Down syndrome
- Author
-
Ganmore, I., Bercovich, D., Scott, L. M., Wainreb, G., Cazzaniga, G., Cario, G., Strehl, S., Binder, V., Kempski, H., Trka, J., Bielorei, B., Stark, B., Smith, O., Dastugue, N., Jean-Pierre Bourquin, Biondi, A., Basso, G., Schrappe, M., Stanulla, M., Haas, O. A., Mann, G., Borkhardt, A., Avigad, S., Ben-Tal, N., Green, A. R., and Izraeli, S.
- Published
- 2008
16. Severe infantile male encephalopathy is a result of early post-zygotic WDR45 somatic mutation.
- Author
-
Spiegel, R., Shalev, S., Bercovich, D., Rabinovich, D., Khayat, M., Shaag, A., and Elpeleg, O.
- Subjects
SOMATIC mutation ,MICROFLUIDICS ,GENETIC disorders in children ,MEDICAL genetics - Abstract
The article describes the case of a male patient who presented with severe early infantile encephalopathy resulting from early post-zygotic WDR45 somatic mutation. Topics discussed include brief clinical description of the patient, the confirmation of the mutation by Sanger sequencing, the analysis of the mutation in the patient's lymphocytes by microfluidic digital polymerase chain reaction (PCR) array technique, and the recommended treatment approach for WDR45 male patients.
- Published
- 2016
- Full Text
- View/download PDF
17. Electromagnetic induction between axons and their schwann cell myelin-protein sheaths
- Author
-
Goodman, G., primary and Bercovich, D., additional
- Published
- 2013
- Full Text
- View/download PDF
18. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
- Author
-
Hertzberg, L, Vendramini, E, Ganmore, I, Cazzaniga, G, Schmitz, M, Chalker, J, Shiloh, R, Iacobucci, I, Shochat, C, Zeligson, S, Cario, G, Stanulla, M, Strehl, S, Russell, L, Harrison, C, Bornhauser, B, Yoda, A, Rechavi, G, Bercovich, D, Borkhardt, A, Kempski, H, te Kronnie, G, Bourquin, J, Domany, E, Izraeli, S, Hertzberg, Libi, Vendramini, Elena, Ganmore, Ithamar, Cazzaniga, Giovanni, Schmitz, Maike, Chalker, Jane, Shiloh, Ruth, Iacobucci, Ilaria, Shochat, Chen, Zeligson, Sharon, Cario, Gunnar, Stanulla, Martin, Strehl, Sabine, Russell, Lisa J, Harrison, Christine J, Bornhauser, Beat, Yoda, Akinori, Rechavi, Gideon, Bercovich, Dani, Borkhardt, Arndt, Kempski, Helena, te Kronnie, Geertruy, Bourquin, Jean-Pierre, Domany, Eytan, Izraeli, Shai, Hertzberg, L, Vendramini, E, Ganmore, I, Cazzaniga, G, Schmitz, M, Chalker, J, Shiloh, R, Iacobucci, I, Shochat, C, Zeligson, S, Cario, G, Stanulla, M, Strehl, S, Russell, L, Harrison, C, Bornhauser, B, Yoda, A, Rechavi, G, Bercovich, D, Borkhardt, A, Kempski, H, te Kronnie, G, Bourquin, J, Domany, E, Izraeli, S, Hertzberg, Libi, Vendramini, Elena, Ganmore, Ithamar, Cazzaniga, Giovanni, Schmitz, Maike, Chalker, Jane, Shiloh, Ruth, Iacobucci, Ilaria, Shochat, Chen, Zeligson, Sharon, Cario, Gunnar, Stanulla, Martin, Strehl, Sabine, Russell, Lisa J, Harrison, Christine J, Bornhauser, Beat, Yoda, Akinori, Rechavi, Gideon, Bercovich, Dani, Borkhardt, Arndt, Kempski, Helena, te Kronnie, Geertruy, Bourquin, Jean-Pierre, Domany, Eytan, and Izraeli, Shai
- Abstract
We report gene expression and other analyses to elucidate the molecular characteristics of acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS). We find that by gene expression DS-ALL is a highly heterogeneous disease not definable as a unique entity. Nevertheless, 62% (33/53) of the DS-ALL samples analyzed were characterized by high expression of the type I cytokine receptor CRLF2 caused by either immunoglobulin heavy locus (IgH@) translocations or by interstitial deletions creating chimeric transcripts P2RY8-CRLF2. In 3 of these 33 patients, a novel activating somatic mutation, F232C in CRLF2, was identified. Consistent with our previous research, mutations in R683 of JAK2 were identified in 10 specimens (19% of the patients) and, interestingly, all 10 had high CRLF2 expression. Cytokine receptor-like factor 2 (CRLF2) and mutated Janus kinase 2 (Jak2) cooperated in conferring cytokine-independent growth to BaF3 pro-B cells. Intriguingly, the gene expression signature of DS-ALL is enriched with DNA damage and BCL6 responsive genes, suggesting the possibility of B-cell lymphocytic genomic instability. Thus, DS confers increased risk for genetically highly diverse ALLs with frequent overexpression of CRLF2, associated with activating mutations in the receptor itself or in JAK2. Our data also suggest that the majority of DS children with ALL may benefit from therapy blocking the CRLF2/JAK2 pathways.
- Published
- 2010
19. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
- Author
-
Bercovich, D, Ganmore, I, Scott, L, Wainreb, G, Birger, Y, Elimelech, A, Shochat, C, Cazzaniga, G, Biondi, A, Basso, G, Cario, G, Schrappe, M, Stanulla, M, Strehl, S, Haas, O, Mann, G, Binder, V, Borkhardt, A, Kempski, H, Trka, J, Bielorei, B, Avigad, S, Stark, B, Smith, O, Dastugue, N, Bourquin, J, Tal, N, Green, A, Izraeli, S, Scott, LM, Haas, OA, Bourquin, JP, Tal, NB, Green, AR, Izraeli, S., BIONDI, ANDREA, Bercovich, D, Ganmore, I, Scott, L, Wainreb, G, Birger, Y, Elimelech, A, Shochat, C, Cazzaniga, G, Biondi, A, Basso, G, Cario, G, Schrappe, M, Stanulla, M, Strehl, S, Haas, O, Mann, G, Binder, V, Borkhardt, A, Kempski, H, Trka, J, Bielorei, B, Avigad, S, Stark, B, Smith, O, Dastugue, N, Bourquin, J, Tal, N, Green, A, Izraeli, S, Scott, LM, Haas, OA, Bourquin, JP, Tal, NB, Green, AR, Izraeli, S., and BIONDI, ANDREA
- Abstract
Background: Children with Down's syndrome have a greatly increased risk of acute megakaryoblastic and acute lymphoblastic leukaemias. Acute megakaryoblastic leukaemia in Down's syndrome is characterised by a somatic mutation in GATA1. Constitutive activation of the JAK/STAT (Janus kinase and signal transducer and activator of transcription) pathway occurs in several haematopoietic malignant diseases. We tested the hypothesis that mutations in JAK2 might be a common molecular event in acute lymphoblastic leukaemia associated with Down's syndrome. Methods: JAK2 DNA mutational analysis was done on diagnostic bone marrow samples obtained from 88 patients with Down's syndrome-associated acute lymphoblastic leukaemia; and 216 patients with sporadic acute lymphoblastic leukaemia, Down's syndrome-associated acute megakaryoblastic leukaemia, and essential thrombocythaemia. Functional consequences of identified mutations were studied in mouse haematopoietic progenitor cells. Findings: Somatically acquired JAK2 mutations were identified in 16 (18%) patients with Down's syndrome-associated acute lymphoblastic leukaemia. The only patient with non-Down's syndrome-associated leukaemia but with a JAK2 mutation had an isochromosome 21q. Children with a JAK2 mutation were younger (mean [SE] age 4·5 years [0·86] vs 8·6 years [0·59], p<0·0001) at diagnosis. Five mutant alleles were identified, each affecting a highly conserved arginine residue (R683). These mutations immortalised primary mouse haematopoietic progenitor cells in vitro, and caused constitutive Jak/Stat activation and cytokine-independent growth of BaF3 cells, which was sensitive to pharmacological inhibition with JAK inhibitor I. In modelling studies of the JAK2 pseudokinase domain, R683 was situated in an exposed conserved region separated from the one implicated in myeloproliferative disorders. Interpretation: A specific genotype-phenotype association exists between the type of somatic mutation within the JAK2 pseudoki
- Published
- 2008
20. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
- Author
-
Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N, Orr-Urtreger, A, Shifrin, C, Rozovski, U, Rosner, S, Bercovich, D, Gurevich, T, Yagev-More, H, Bar-Shira, A, and Giladi, N
- Published
- 2007
- Full Text
- View/download PDF
21. High Frequency of BRCA 1/2 Mutations Among Israeli Non Ashkenazi Breast Cancer Patients
- Author
-
Elyan, F., primary, Maimon, O., additional, Salah, A.F., additional, Sagi, M., additional, Kaduri, L., additional, Lerer, I., additional, Goldberg, Y., additional, Hamburger, T., additional, Bercovich, D., additional, and Peretz-Yablonski, T., additional
- Published
- 2012
- Full Text
- View/download PDF
22. SFB‐based S‐haplotyping of apricot (Prunus armeniaca) with DHPLC
- Author
-
Raz, A., primary, Stern, R. A., additional, Bercovich, D., additional, and Goldway, M., additional
- Published
- 2009
- Full Text
- View/download PDF
23. Effect of single-nucleotide polymorphisms in the CYP19 gene on response to Letrozole among breast cancer patients
- Author
-
Kadouri, l., primary, Bercovich, D., additional, Rottenberg, Y., additional, Korem, S., additional, Elimelech, A., additional, Uziely, B., additional, Safra, T., additional, Ron, I. G., additional, Peretz, T., additional, and Yaal-Hahoshen, N., additional
- Published
- 2008
- Full Text
- View/download PDF
24. Denaturing High-Performance Liquid Chromatography for the Detection of Mutations and Polymorphisms inUBE3A
- Author
-
Bercovich, D., primary and Beaudet, A. L., additional
- Published
- 2003
- Full Text
- View/download PDF
25. Characterization of the human β4 nAChR gene and polymorphisms in CHRNA3 and CHRNB4
- Author
-
Lev-Lehman, E., primary, Bercovich, D., additional, Xu, W., additional, Stockton, D. W., additional, and Beaudet, A. L., additional
- Published
- 2001
- Full Text
- View/download PDF
26. Identification of a starting point of breast skin tears during chicken plucking
- Author
-
Pitcovski, J, primary, Ohana, N, additional, Amzaleg, L, additional, Krispel, S, additional, Bercovich, D, additional, and Pinchasov, Y, additional
- Published
- 1997
- Full Text
- View/download PDF
27. The LRRK2G2019S mutation in Ashkenazi Jews with Parkinson disease
- Author
-
Orr-Urtreger, A, Shifrin, C, Rozovski, U, Rosner, S, Bercovich, D, Gurevich, T, Yagev-More, H, Bar-Shira, A, and Giladi, N
- Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic determinant of Parkinson disease (PD) identified to date, and have been implicated in both familial and sporadic forms of the disease. The G2019S change in LRRK2exon 41 has been associated with disease at varying frequencies in Asian, European, North American, and North African populations, and is particularly prevalent among Ashkenazi Jews.
- Published
- 2007
- Full Text
- View/download PDF
28. W14.378 CETP and MDR1 SNP-haplotypes are associated with lipid lowering effect of fluvastatin in familial hypercholesterolemia
- Author
-
Meiner, V., Bercovich, D., Friedlander, Y., and Leitersdorf, E.
- Published
- 2004
- Full Text
- View/download PDF
29. Familial adenomatous polyposis
- Author
-
Rozen Paul, Bercovich Dani, and Half Elizabeth
- Subjects
Medicine - Abstract
Abstract Familial adenomatous polyposis (FAP) is characterized by the development of many tens to thousands of adenomas in the rectum and colon during the second decade of life. FAP has an incidence at birth of about 1/8,300, it manifests equally in both sexes, and accounts for less than 1% of colorectal cancer (CRC) cases. In the European Union, prevalence has been estimated at 1/11,300-37,600. Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops. Generally, cancers start to develop a decade after the appearance of the polyps. Nonspecific symptoms may include constipation or diarrhea, abdominal pain, palpable abdominal masses and weight loss. FAP may present with some extraintestinal manifestations such as osteomas, dental abnormalities (unerupted teeth, congenital absence of one or more teeth, supernumerary teeth, dentigerous cysts and odontomas), congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors, and extracolonic cancers (thyroid, liver, bile ducts and central nervous system). A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk. Some lesions (skull and mandible osteomas, dental abnormalities, and fibromas on the scalp, shoulders, arms and back) are indicative of the Gardner variant of FAP. Classic FAP is inherited in an autosomal dominant manner and results from a germline mutation in the adenomatous polyposis (APC) gene. Most patients (~70%) have a family history of colorectal polyps and cancer. In a subset of individuals, a MUTYH mutation causes a recessively inherited polyposis condition, MUTYH-associated polyposis (MAP), which is characterized by a slightly increased risk of developing CRC and polyps/adenomas in both the upper and lower gastrointestinal tract. Diagnosis is based on a suggestive family history, clinical findings, and large bowel endoscopy or full colonoscopy. Whenever possible, the clinical diagnosis should be confirmed by genetic testing. When the APC mutation in the family has been identified, genetic testing of all first-degree relatives should be performed. Presymptomatic and prenatal (amniocentesis and chorionic villous sampling), and even preimplantation genetic testing is possible. Referral to a geneticist or genetic counselor is mandatory. Differential diagnoses include other disorders causing multiple polyps (such as Peutz-Jeghers syndrome, familial juvenile polyps or hyperplastic polyposis, hereditary mixed polyposis syndromes, and Lynch syndrome). Cancer prevention and maintaining a good quality of life are the main goals of management and regular and systematic follow-up and supportive care should be offered to all patients. By the late teens or early twenties, colorectal cancer prophylactic surgery is advocated. The recommended alternatives are total proctocolectomy and ileoanal pouch or ileorectal anastomosis for AFAP. Duodenal cancer and desmoids are the two main causes of mortality after total colectomy, they need to be identified early and treated. Upper endoscopy is necessary for surveillance to reduce the risk of ampullary and duodenal cancer. Patients with progressive tumors and unresectable disease may respond or stabilize with a combination of cytotoxic chemotherapy and surgery (when possible to perform). Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP. Individuals with FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program.
- Published
- 2009
- Full Text
- View/download PDF
30. A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer
- Author
-
Nissan Aviram, Hamburger Tamar, Korem Sigal, Shochat Chen, Glusman Gila, Sagi Michal, Lerer Israela, Elimelech Arava, Bercovich Dani, Kadouri Luna, Abu-Halaf Nahil, Badrriyah Muhmud, Abeliovich Dvorah, and Peretz Tamar
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The incidence of breast cancer (BC) in Arab women is lower compared to the incidence in the Jewish population in Israel; still, it is the most common malignancy among Arab women. There is a steep rise in breast cancer incidence in the Arab population in Israel over the last 10 years that can be attributed to life style changes. But, the younger age of BC onset in Arab women compared with that of the Jewish population is suggestive of a genetic component in BC occurrence in that population. Methods We studied the family history of 31 women of Palestinian Arab (PA) origin affected with breast (n = 28), ovarian (n = 3) cancer. We used denaturing high performance liquid chromatography (DHPLC) to screen for mutations of BRCA1/2 in 4 women with a personal and family history highly suggestive of genetic predisposition. Results A novel BRCA1 mutation, E1373X in exon 12, was found in a patient affected with ovarian cancer. Four of her family members, 3 BC patients and a healthy individual were consequently also found to carry this mutation. Of the other 27 patients, which were screened for this specific mutation none was found to carry it. Conclusion We found a novel BRCA1 mutation in a family of PA origin with a history highly compatible with BRCA1 phenotype. This mutation was not found in additional 30 PA women affected with BC or OC. Therefore full BRCA1/2 screening should be offered to patients with characteristic family history. The significance of the novel BRCA1 mutation we identified should be studied in larger population. However, it is likely that the E1373X mutation is not a founder frequent mutation in the PA population.
- Published
- 2007
- Full Text
- View/download PDF
31. Familial adenomatous polyposis.
- Author
-
Half E, Bercovich D, Rozen P, Half, Elizabeth, Bercovich, Dani, and Rozen, Paul
- Abstract
Familial adenomatous polyposis (FAP) is characterized by the development of many tens to thousands of adenomas in the rectum and colon during the second decade of life. FAP has an incidence at birth of about 1/8,300, it manifests equally in both sexes, and accounts for less than 1% of colorectal cancer (CRC) cases. In the European Union, prevalence has been estimated at 1/11,300-37,600. Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops. Generally, cancers start to develop a decade after the appearance of the polyps. Nonspecific symptoms may include constipation or diarrhea, abdominal pain, palpable abdominal masses and weight loss. FAP may present with some extraintestinal manifestations such as osteomas, dental abnormalities (unerupted teeth, congenital absence of one or more teeth, supernumerary teeth, dentigerous cysts and odontomas), congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors, and extracolonic cancers (thyroid, liver, bile ducts and central nervous system). A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk. Some lesions (skull and mandible osteomas, dental abnormalities, and fibromas on the scalp, shoulders, arms and back) are indicative of the Gardner variant of FAP. Classic FAP is inherited in an autosomal dominant manner and results from a germline mutation in the adenomatous polyposis (APC) gene. Most patients (~70%) have a family history of colorectal polyps and cancer. In a subset of individuals, a MUTYH mutation causes a recessively inherited polyposis condition, MUTYH-associated polyposis (MAP), which is characterized by a slightly increased risk of developing CRC and polyps/adenomas in both the upper and lower gastrointestinal tract. Diagnosis is based on a suggestive family history, clinical findings, and large bowel endoscopy or full colonoscopy. Whenever possible, the clinical diagnosis should be confirmed by genetic testing. When the APC mutation in the family has been identified, genetic testing of all first-degree relatives should be performed. Presymptomatic and prenatal (amniocentesis and chorionic villous sampling), and even preimplantation genetic testing is possible. Referral to a geneticist or genetic counselor is mandatory. Differential diagnoses include other disorders causing multiple polyps (such as Peutz-Jeghers syndrome, familial juvenile polyps or hyperplastic polyposis, hereditary mixed polyposis syndromes, and Lynch syndrome). Cancer prevention and maintaining a good quality of life are the main goals of management and regular and systematic follow-up and supportive care should be offered to all patients. By the late teens or early twenties, colorectal cancer prophylactic surgery is advocated. The recommended alternatives are total proctocolectomy and ileoanal pouch or ileorectal anastomosis for AFAP. Duodenal cancer and desmoids are the two main causes of mortality after total colectomy, they need to be identified early and treated. Upper endoscopy is necessary for surveillance to reduce the risk of ampullary and duodenal cancer. Patients with progressive tumors and unresectable disease may respond or stabilize with a combination of cytotoxic chemotherapy and surgery (when possible to perform). Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP. Individuals with FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
32. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia
- Author
-
Chen Shochat, Marc R. Mansour, Dani Bercovich, Vitalina Gryshkova, Nava Gershman, Obul Reddy Bandapalli, Nir Ben-Tal, Jean-Claude Twizere, Giovanni Cazzaniga, Yehudit Birger, Martina U. Muckenthaler, Shai Izraeli, Noa Tal, Andreas E. Kulozik, Andrea Biondi, Stefan N. Constantinescu, Shochat, C, Tal, N, Gryshkova, V, Birger, Y, Bandapalli, O, Cazzaniga, G, Gershman, N, Kulozik, A, Biondi, A, Mansour, M, Twizere, J, Muckenthaler, M, Ben-Tal, N, Constantinescu, S, Bercovich, D, and Izraeli, S
- Subjects
Blotting, Western ,DNA Mutational Analysis ,Molecular Sequence Data ,Immunology ,Biology ,Mutagenesi ,Biochemistry ,DNA Mutational Analysi ,Mice ,Transduction, Genetic ,medicine ,Animals ,Humans ,Amino Acid Sequence ,Cysteine ,Receptors, Cytokine ,Receptor ,Interleukin-7 receptor ,Cells, Cultured ,Mice, Inbred BALB C ,Receptors, Interleukin-7 ,Base Sequence ,Animal ,Kinase ,Medicine (all) ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Flow Cytometry ,medicine.disease ,Molecular biology ,Transmembrane protein ,Complementation ,Transmembrane domain ,Leukemia ,Mutagenesis ,Mutation ,Heterografts ,Female ,Signal transduction ,Heterograft ,Human ,Signal Transduction - Abstract
Gain-of-function somatic mutations introducing cysteines to either the extracellular or to the transmembrane domain (TMD) in interleukin-7 receptor α (IL7R) or cytokine receptor-like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD closer to the cytosolic domain. Biochemical and functional assays showed that these are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells in vitro and are transforming in vivo. Protein fragment complementation assays suggest that despite the absence of cysteines, the mechanism of activation is through ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations suggest that the mutations stabilize the homodimeric conformation, positioning the cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous receptor activation independently of external signals. Hence, type I cytokine receptors may be activated in leukemia through 2 types of transmembrane somatic dimerizing mutations.
- Published
- 2014
- Full Text
- View/download PDF
33. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
- Author
-
Jane Chalker, Chen Shochat, Maike Schmitz, Eytan Domany, Geertruy te Kronnie, Beat Bornhauser, Jean-Pierre Bourquin, Ilaria Iacobucci, Martin Stanulla, Elena Vendramini, Giovanni Cazzaniga, Christine J. Harrison, Shai Izraeli, Gideon Rechavi, Sabine Strehl, Sharon Zeligson, Lisa J. Russell, Arndt Borkhardt, Ithamar Ganmore, Libi Hertzberg, Akinori Yoda, Gunnar Cario, Helena Kempski, Dani Bercovich, Ruth Shiloh, University of Zurich, Izraeli, S, Hertzberg, L, Vendramini, E, Ganmore, I, Cazzaniga, G, Schmitz, M, Chalker, J, Shiloh, R, Iacobucci, I, Shochat, C, Zeligson, S, Cario, G, Stanulla, M, Strehl, S, Russell, L, Harrison, C, Bornhauser, B, Yoda, A, Rechavi, G, Bercovich, D, Borkhardt, A, Kempski, H, te Kronnie, G, Bourquin, J, and Domany, E
- Subjects
1303 Biochemistry ,DNA-Binding Protein ,Immunology ,Blotting, Western ,2720 Hematology ,610 Medicine & health ,medicine.disease_cause ,Biochemistry ,Cell Line ,1307 Cell Biology ,Genetic Heterogeneity ,Germline mutation ,Acute lymphocytic leukemia ,medicine ,Animals ,Humans ,Receptors, Cytokine ,Child ,Gene ,In Situ Hybridization, Fluorescence ,Immunoglobulin heavy locus ,Regulation of gene expression ,Mutation ,2403 Immunology ,Janus kinase 2 ,biology ,Animal ,Gene Expression Regulation, Leukemic ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression Profiling ,Cell Biology ,Hematology ,Janus Kinase 2 ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Flow Cytometry ,Molecular biology ,DNA-Binding Proteins ,Gene expression profiling ,10036 Medical Clinic ,Cancer research ,biology.protein ,Proto-Oncogene Proteins c-bcl-6 ,Down Syndrome ,Human ,Signal Transduction - Abstract
We report gene expression and other analyses to elucidate the molecular characteristics of acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS). We find that by gene expression DS-ALL is a highly heterogeneous disease not definable as a unique entity. Nevertheless, 62% (33/53) of the DS-ALL samples analyzed were characterized by high expression of the type I cytokine receptor CRLF2 caused by either immunoglobulin heavy locus (IgH@) translocations or by interstitial deletions creating chimeric transcripts P2RY8-CRLF2. In 3 of these 33 patients, a novel activating somatic mutation, F232C in CRLF2, was identified. Consistent with our previous research, mutations in R683 of JAK2 were identified in 10 specimens (19% of the patients) and, interestingly, all 10 had high CRLF2 expression. Cytokine receptor-like factor 2 (CRLF2) and mutated Janus kinase 2 (Jak2) cooperated in conferring cytokine-independent growth to BaF3 pro-B cells. Intriguingly, the gene expression signature of DS-ALL is enriched with DNA damage and BCL6 responsive genes, suggesting the possibility of B-cell lymphocytic genomic instability. Thus, DS confers increased risk for genetically highly diverse ALLs with frequent overexpression of CRLF2, associated with activating mutations in the receptor itself or in JAK2. Our data also suggest that the majority of DS children with ALL may benefit from therapy blocking the CRLF2/JAK2 pathways.
- Published
- 2010
34. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
- Author
-
Jan Trka, Chen Shochat, Nicole Dastugue, Smadar Avigad, Giuseppe Basso, Gilad Wainreb, Arndt Borkhardt, Andrea Biondi, Arava Elimelech, Yehudit Birger, Owen P. Smith, Martin Schrappe, Nir Ben Tal, Sabine Strehl, Shai Izraeli, Batia Stark, Vera Binder, Jean-Pierre Bourquin, Anthony R. Green, Bella Bielorei, Gunnar Cario, Ithamar Ganmore, Giovanni Cazzaniga, Helena Kempski, Dani Bercovich, Martin Stanulla, Linda M. Scott, Oskar A. Haas, Georg Mann, University of Zurich, Izraeli, S, Bercovich, D, Ganmore, I, Scott, L, Wainreb, G, Birger, Y, Elimelech, A, Shochat, C, Cazzaniga, G, Biondi, A, Basso, G, Cario, G, Schrappe, M, Stanulla, M, Strehl, S, Haas, O, Mann, G, Binder, V, Borkhardt, A, Kempski, H, Trka, J, Bielorei, B, Avigad, S, Stark, B, Smith, O, Dastugue, N, Bourquin, J, Tal, N, and Green, A
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Myeloid ,Genotype ,Isochromosome ,610 Medicine & health ,2700 General Medicine ,Mice ,Polycythemia vera ,Germline mutation ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Animals ,Humans ,GATA1 Transcription Factor ,Child ,Cells, Cultured ,business.industry ,Cancer ,GATA1 ,General Medicine ,Janus Kinase 2 ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,JAK2 in acute lymphoblastic leukaemia ,Mice, Inbred C57BL ,Haematopoiesis ,medicine.anatomical_structure ,10036 Medical Clinic ,Child, Preschool ,Immunology ,Mutation ,Female ,Down Syndrome ,Trisomy ,business - Abstract
Background: Children with Down's syndrome have a greatly increased risk of acute megakaryoblastic and acute lymphoblastic leukaemias. Acute megakaryoblastic leukaemia in Down's syndrome is characterised by a somatic mutation in GATA1. Constitutive activation of the JAK/STAT (Janus kinase and signal transducer and activator of transcription) pathway occurs in several haematopoietic malignant diseases. We tested the hypothesis that mutations in JAK2 might be a common molecular event in acute lymphoblastic leukaemia associated with Down's syndrome. Methods: JAK2 DNA mutational analysis was done on diagnostic bone marrow samples obtained from 88 patients with Down's syndrome-associated acute lymphoblastic leukaemia; and 216 patients with sporadic acute lymphoblastic leukaemia, Down's syndrome-associated acute megakaryoblastic leukaemia, and essential thrombocythaemia. Functional consequences of identified mutations were studied in mouse haematopoietic progenitor cells. Findings: Somatically acquired JAK2 mutations were identified in 16 (18%) patients with Down's syndrome-associated acute lymphoblastic leukaemia. The only patient with non-Down's syndrome-associated leukaemia but with a JAK2 mutation had an isochromosome 21q. Children with a JAK2 mutation were younger (mean [SE] age 4·5 years [0·86] vs 8·6 years [0·59], p
- Published
- 2008
- Full Text
- View/download PDF
35. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
- Author
-
Shai Izraeli, Gunnar Cario, Martina U. Muckenthaler, Giuseppe Basso, Andreas E. Kulozik, Andrea Biondi, Ithamar Ganmore, Noa Tal, Martin Schrappe, Obul Reddy Bandapalli, Dani Bercovich, Geertruy te Kronnie, Chen Shochat, Giovanni Cazzaniga, Chiara Palmi, Martin Stanulla, Shochat, C, Tal, N, Bandapalli, O, Palmi, C, Ganmore, I, Te Kronnie, G, Cario, G, Cazzaniga, G, Kulozik, A, Stanulla, M, Schrappe, M, Biondi, A, Basso, G, Bercovich, D, Muckenthaler, M, and Izraeli, S
- Subjects
Male ,Thymic stromal lymphopoietin ,Adolescent ,Immunology ,Mutant ,Biology ,medicine.disease_cause ,Cell Line ,03 medical and health sciences ,Text mining ,0302 clinical medicine ,Thymic Stromal Lymphopoietin ,IL7 receptor, Childhood ALL ,medicine ,Humans ,Immunology and Allergy ,Receptors, Cytokine ,Child ,Interleukin-7 receptor ,Receptor ,B cell ,030304 developmental biology ,Genetics ,0303 health sciences ,Mutation ,Receptors, Interleukin-7 ,business.industry ,Brief Definitive Report ,Correction ,Lymphoid Progenitor Cells ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Molecular biology ,Protein Structure, Tertiary ,3. Good health ,Leukemia ,Gain of function ,Interleukin-7 receptor-α ,medicine.anatomical_structure ,Amino Acid Substitution ,Child, Preschool ,030220 oncology & carcinogenesis ,Cancer research ,Acute lymphoblastic leukemias ,Cytokines ,Female ,business - Abstract
IL7R-activating mutations identified in B-ALL and T-ALL patient leukemic cells facilitate cytokine-independent growth., Interleukin-7 receptor α (IL7R) is required for normal lymphoid development. Loss-of-function mutations in this gene cause autosomal recessive severe combined immune deficiency. Here, we describe somatic gain-of-function mutations in IL7R in pediatric B and T acute lymphoblastic leukemias. The mutations cause either a serine-to-cysteine substitution at amino acid 185 in the extracellular domain (4 patients) or in-frame insertions and deletions in the transmembrane domain (35 patients). In B cell precursor leukemias, the mutations were associated with the aberrant expression of cytokine receptor-like factor 2 (CRLF2), and the mutant IL-7R proteins formed a functional receptor with CRLF2 for thymic stromal lymphopoietin (TSLP). Biochemical and functional assays reveal that these IL7R mutations are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells. A cysteine, included in all but three of the mutated IL-7R alleles, is essential for the constitutive activation of the receptor. This is the first demonstration of gain-of-function mutations of IL7R. Our current and recent observations of mutations in IL7R and CRLF2, respectively suggest that the addition of cysteine to the juxtamembranous domains is a general mechanism for mutational activation of type I cytokine receptors in leukemia.
- Published
- 2011
36. High Prevalence of Hearing Impairment in Primary Congenital Hypothyroidism.
- Author
-
Almagor T, Rath S, Nachtigal D, Sharroni Z, Elias-Assad G, Hess O, Havazelet G, Zehavi Y, Spiegel R, Bercovich D, Almashanu S, and Tenenbaum-Rakover Y
- Abstract
Background: An association between hearing impairment (HI) and congenital hypothyroidism (CH) has been reported previously. However, in general, studies were retrospective and had small sample sizes, and the results were variable and inconclusive. The aim of our study was to assess the prevalence of HI among patients with CH and to examine factors potentially predictive of HI including severity of CH, etiology of CH, and timing of treatment initiation., Methods: Audiometry was undertaken prospectively in 66 patients aged 3-21 years diagnosed with primary CH and 49 healthy matched controls. All patients with HI underwent examination by an otolaryngologist, and in patients with sensorineural loss, brainstem evoked response audiometry was performed. A next-generation sequencing (NGS) panel for genes involved in deafness was performed in patients with sensorineural HI to exclude additional genetic etiologies., Results: HI was found in 19 patients (28.7%). Among them, 5 (7.6%) had moderate to severe bilateral sensorineural impairment and 14 (21.2%) had mild conductive HI. Conductive HI was bilateral in 5 of these patients (36%). None of the controls had HI. No specific etiology was found in patients with HI, and no differences were identified in age at diagnosis, age at initiation of levothyroxine (LT
4 ) therapy, gender, or ethnicity between patients with and without HI. A nonsignificant trend toward lower mean screening TT4 levels was found in patients with HI (compared to those without HI) (3.42 vs. 5.34 μg/dL, p = 0.095). No pathogenic variants in genes attributed to HI were identified by NGS in the 5 patients with sensorineural deafness, indicating that HI in these patients was likely attributable to CH rather than other genetic etiologies., Conclusions: Our findings indicate a high prevalence of HI among patients with CH, predominantly of the conductive type. HI was not associated with the etiology of CH or with delayed initiation of LT4 therapy. Audiometry is recommended for children diagnosed with CH and repeat monitoring may be warranted to identify acquired HI and to prevent long-term sequelae of undiagnosed deafness., Competing Interests: All authors have nothing to disclose., (Copyright © 2020 by S. Karger AG, Basel.)- Published
- 2021
- Full Text
- View/download PDF
37. A case of Ververi-Brady syndrome due to QRICH1 loss of function and the literature review.
- Author
-
Baruch Y, Horn-Saban S, Plotsky Y, Bercovich D, and Gershoni-Baruch R
- Subjects
- Child, Child, Preschool, Chromosomes, Human, Pair 3 genetics, Developmental Disabilities pathology, Female, Humans, Infant, Intellectual Disability pathology, Language Development Disorders pathology, Loss of Function Mutation genetics, Male, Phenotype, DNA-Binding Proteins genetics, Developmental Disabilities genetics, Intellectual Disability genetics, Language Development Disorders genetics, Transcription Factors genetics
- Abstract
Ververi-Brady syndrome (VBS), first reported in 2018, is characterized by intellectual disability, speech delay, and mild dysmorphic facial features. VBS has been linked to de novo loss-of-function variants in the glutamine-rich protein 1 (QRICH1) on chromosome 3p21 and was reported until lately in only five individuals. Four additional cases have just been described substantiating the notion that children with VBS are mildly dysmorphic, mildly to moderately intellectually disabled, have linear growth shortage, are picky eaters, and have notable attention and social behavioral deficits. We describe a new patient and review the clinical and genetic information, on all previously reported VBS cases. The child here reported is noted for maladaptive behavior, sensory hypersensitivity, and slow linear growth. He is mainly hyperactive, distractible, impulsive, and inattentive. His speech, initially delayed, is fair and his verbal comprehension age adequate., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
38. Extreme Short Stature and Severe Neurological Impairment in a 17-Year-Old Male With Untreated Combined Pituitary Hormone Deficiency Due to POU1F1 Mutation.
- Author
-
Majdoub H, Amselem S, Legendre M, Rath S, Bercovich D, and Tenenbaum-Rakover Y
- Abstract
Background: POU1F1 is an essential transcription factor for the differentiation, proliferation and survival of somatotrophs, lactotrophs, and thyrotrophs. Mutations in the POU1F1 gene are characterized by growth hormone (GH), thyrotropin, and prolactin deficiencies, commonly presenting with growth retardation and central hypothyroidism. Since the first report in 1992, more than 25 mutations have been identified in POU1F1 . Case Description: We describe a 17-year-old male who presented to our Pediatric Endocrinology clinic with extreme short stature (height 81.7 cm, -9.3 SD), cognitive impairment, deaf-mutism, and neurological disabilities. L-thyroxine supplemental therapy, which had been initiated at the age of 6 months but ceased due to non-compliance, was reintroduced at presentation. GH therapy was initiated at 19 years of age, resulting in 42 cm linear growth, to a final height of 124 cm. Sequencing of POU1F1 revealed a previously described homozygous insertion mutation-c.580_581insT, p (Thr194Ilefs
* 7)-in exon 4 causing a frameshift that introduces a stop codon 7 amino acids downstream, leading to a severely truncated protein lacking the homeodomain. Conclusion: This case report sheds light on the natural history of untreated patients with POU1F1 mutations and raises awareness for early diagnosis and adequate treatment of central congenital hypothyroidism and GH deficiency.- Published
- 2019
- Full Text
- View/download PDF
39. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
- Author
-
Rosner G, Gluck N, Carmi S, Bercovich D, Fliss-Issakov N, Ben-Yehoyada M, Aharon-Caspi S, Kellerman E, Strul H, Shibolet O, and Kariv R
- Subjects
- Adenoma ethnology, Adult, Aged, Colorectal Neoplasms ethnology, DNA Mismatch Repair, Female, Genetic Association Studies, Genetic Predisposition to Disease, Humans, Jews, Male, Middle Aged, Mutation, Prevalence, Registries, Adenoma genetics, Colorectal Neoplasms genetics, DNA Polymerase II genetics, DNA Polymerase III genetics, Poly-ADP-Ribose Binding Proteins genetics
- Abstract
Background: Germline mutations in the DNA polymerase genes POLD1 and POLE confer high risk for multiple colorectal adenomas and colorectal cancer. However, prevalence and the clinical phenotype of mutation carriers are still not fully characterized., Objective: The purpose of this study was to assess the prevalence of germline mutations and to describe the genotype-phenotype correlation in POLD1 and POLE genes in Jewish subjects with multiple colorectal adenomas and/or early-onset mismatch repair proficient colorectal cancers., Design: This study is a comparison of genetic and clinical data from affected and control groups., Settings: The study was conducted at a high-volume tertiary referral center., Patients: The study cohort included 132 subjects: 68 with multiple colorectal adenomas and 64 with early-onset mismatch repair proficient colorectal cancers. The control group included 5685 individuals having no colorectal cancer or colorectal adenomas., Main Outcome Measures: Study and control subjects were tested for POLD1 and POLE mutations and a clinical correlation was assessed., Results: Eleven of the 132 study subjects (8.3%) carried either a POLD1 or a POLE mutation: 7 of 68 (10.3%) subjects with multiple colorectal adenomas and 4 of 64 (6.2%) subjects with early-onset mismatch repair proficient colorectal cancer. Three mutations were detected, showing statistical significance in frequency between study and control groups (p < 0.001). Eight of the 11 mutation carriers were Ashkenazi Jews carrying the same POLD1 mutation (V759I), implicating it as a possible low-to-moderate risk founder mutation. Phenotype of mutation carriers was notable for age under 50 at diagnosis, a propensity toward left-sided colorectal cancer, and extracolonic tumors (64%, 100%, and 27% of cases)., Limitations: The study cohort was limited by its relatively small size., Conclusions: Germline mutations in POLD1 and POLE were found to be relatively frequent in our Jewish cohorts. Further studies are needed to clarify the importance of POLD1 and POLE mutations and to define the most suitable surveillance program for Jewish and other POLD1 and POLE mutation carriers. See Video Abstract at http://links.lww.com/DCR/A658.
- Published
- 2018
- Full Text
- View/download PDF
40. The significance of human spermatozoa vacuoles can be elucidated by a novel procedure of array comparative genomic hybridization.
- Author
-
Berkovitz A, Dekel Y, Goldstein R, Bsoul S, Machluf Y, and Bercovich D
- Subjects
- Comparative Genomic Hybridization, DNA Copy Number Variations, Humans, Infertility, Male metabolism, Male, Semen Analysis methods, Genomic Instability physiology, Infertility, Male diagnosis, Spermatozoa metabolism, Vacuoles metabolism
- Abstract
Study Question: Is there an association between spermatozoon genomic stability and vacuolar morphology and location?, Summary Answer: The genomic stability of spermatozoa is associated with specific characteristics of vacuolar morphology (depth) and location (cellular compartment, i.e. nucleus and equatorial region)., What Is Known Already: Genetic anomalies in sperm are correlated with semen abnormalities, yet the advantage of morphologically based selection of spermatozoa for IVF according to current criteria is controversial. Selection criteria based on the number of vacuoles and their size have been proposed and are widely applied. Nevertheless, it has not improved the ICSI success rates, suggesting the currently used vacuole criteria are incomplete., Study Design, Size, Duration: Normal sperm according to Motile Sperm Organelle Morphology Examination criteria (MSOME) and common vacuole grading were evaluated. An additional evaluation of sperm vacuole morphology according to novel vacuole criteria (i.e. location and depth) was conducted. An assessment to align these specific vacuolar morphology features with genomic stability was conducted among spermatozoa from infertile patients and healthy fertile donors aged 24-38 between June 2015 and July 2016., Participants/materials, Setting, Methods: Single spermatozoa (n = 53) from 16 infertile patients and 14 fertile donors were morphologically and genetically evaluated. Each spermatozoon was examined morphologically, by ultra-magnification ×6300, and genetically by a novel comparative genomic hybridization protocol, without the use of reference DNA, to assess chromosomal instability as evident by copy number variations (CNV)., Main Results and the Role of Chance: We established an association between genomic stability and vacuolar morphology as a base for a new classification according to novel vacuolar criteria, specifically depth and location. Genomic instability was found to be related to these two main features of vacuoles and, surprisingly not to the number and size of vacuoles as in the previously proposed classifications. High CNV spermatozoa were characterized by vacuoles located in the nucleus and/or equatorial segment or by deep vacuoles, while, low CNV spermatozoa were characterized by a complete lack of vacuoles or non-deep vacuoles not located in the nucleus/equatorial segment. A putative threshold of ~265 CNV was deduced to distinguish between genetically stable and unstable spermatozoa, and 94% of the tested spermatozoa segregated accordingly., Limitations Reasons for Caution: A relatively small sample of spermatozoa were examined-53 in total. However, the association between vacuoles location and morphology and genomic stability was significant. This is the first study evaluating spermatozoon genomic stability with respect to vacuole morphology according to novel vacuole criteria (i.e. location and depth) and further investigation is warranted to verify the value of these criteria in larger sample size clinical studies., Wider Implications of the Findings: Our results, which are based on spermatozoon vacuoles morphological classification and genomic parameters, indicate an association between vacuoles morphology and location and genomic stability. The data presented herein suggest the existence of subpopulations of spermatozoa potentially appropriate for IVF-ICSI, as they appear normal according to the current MSOME and vacuoles classification, however they are almost certainly genetically damaged. As current criteria have yet to achieve an unequivocal evaluation of the implantation potential of a given spermatozoon, we propose novel criteria, based on specific vacuolar morphological traits; depth and location, as these were found aligned with genomic findings., Study Funding/competing Interest(s): No funding was received for this study. The authors have no conflict of interest to declare., Trial Registration Number: N/A.
- Published
- 2018
- Full Text
- View/download PDF
41. Frequency of canine nt230(del4) MDR1 mutation in prone pure breeds, their crosses and mongrels in Israel - insights from a worldwide comparative perspective.
- Author
-
Dekel Y, Machluf Y, Stoler A, Aderet A, Baumel D, Kellerman E, Plotsky Y, Noked Partouche O, Elhalal G, Ben-Shlomo I, and Bercovich D
- Subjects
- Alleles, Animals, Breeding, DNA Mutational Analysis, Female, Israel, Male, Sequence Deletion, Species Specificity, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Dogs genetics, Gene Frequency, Mutation
- Abstract
Background: Sensitivity to macrocyclic lactones, which are commonly used in veterinary clinics, was first found in Rough Collies, and was attributed in 2001 to a 4 bp deletion in the MDR1 gene. The list of affected breeds currently includes 13 breeds. Researchers from different countries and continents examined the allelic frequencies of the nt230(del4) MDR1 mutation, emphasizing the clinical importance of this test not only to mutation-prone dogs, but also to their crosses and mongrels, since treatment of a deletion carrier with these compounds may lead to its death. In this study, the allelic frequencies of nt230(del4) MDR1 mutation in affected breeds, their crosses, unrelated pure breeds and mongrels are reported for the state of Israel (n = 1416 dogs). The Israeli data were compared with reports from the US, Europe, UK, Australia and Japan., Results: The allelic frequencies of nt230(del4) MDR1 mutation in Israel for Australian, Swiss and German Shepherds (31%, 17% and 2.4%, respectively) are similar to the corresponding frequencies worldwide, much higher for Border Collies (4.8%), twice lower for Rough Collies (28%, compared to 55% or more elsewhere), and ~1% for mongrels. The frequencies for crosses of Australian Shepherd and Border Collies in Israel are 4 and 1.6 times lower, respectively, compared to the frequencies for the respective pure breeds., Conclusions: This work, that for the first time presents the frequency of nt230(del4) MDR1 mutation in Israel, along with a worldwide survey, has implications for clinicians, owners and breeders of sheepdogs and their crosses and supports the need for extra care in treatment and in future breeding. Of note, the relative proportion of affected breeds, in the overall tested dogs, might be higher than their actual proportion in Israel due to directed samples collection by veterinarians for clinical purposes, as these are mainly limited to certain affected breeds or dogs that resemble them.
- Published
- 2017
- Full Text
- View/download PDF
42. Mammal domestication and the symbiotic spectrum.
- Author
-
Dekel Y, Machluf Y, Brand R, Noked Partouche O, Ben-Shlomo I, and Bercovich D
- Subjects
- Animals, Crops, Agricultural, Humans, Mammals, Domestication, Symbiosis
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
43. Familial Central Hypothyroidism Caused by a Novel IGSF1 Gene Mutation.
- Author
-
Tenenbaum-Rakover Y, Turgeon MO, London S, Hermanns P, Pohlenz J, Bernard DJ, and Bercovich D
- Subjects
- Child, Preschool, DNA Mutational Analysis, HEK293 Cells, Humans, Infant, Infant, Newborn, Male, Mutation, Receptors, Thyrotropin-Releasing Hormone genetics, Siblings, Thyrotropin genetics, Thyrotropin-Releasing Hormone genetics, Congenital Hypothyroidism genetics, Hypothyroidism genetics, Immunoglobulins genetics, Membrane Proteins genetics
- Abstract
Background: Congenital hypothyroidism of central origin (CH-C) is a rare disease in which thyroid hormone deficiency is caused by insufficient thyrotropin stimulation of a normal thyroid gland. A recently described syndrome of isolated CH-C and macroorchidism was attributed to loss-of-function mutations of the immunoglobulin superfamily, member 1 gene (IGSF1)., Patients and Methods: CH-C was diagnosed in three siblings. The TRH, TRHR, and TSHB genes were sequenced followed by whole-exome sequencing in the proband. A mutation identified in IGSF1 was analyzed by direct PCR sequencing in family members. The effects of the mutation were assessed by in vitro studies in HEK293 cells., Results: The index case was negative for mutations in TRH, TRHR, and TSHB. Whole-exome sequencing revealed a novel insertion mutation in IGSF1, c.2284_2285insA, p.R762QfsX7, which was confirmed by direct PCR sequencing and was identified in six additional family members. The mutation introduces a frame-shift and premature stop codon in the seventh Ig loop, thereby truncating IGSF1. In vitro studies revealed that the mutated IGSF1-R762QfsX7 migrates as a doublet at ∼28 kDa, which is far smaller than the wild type protein (130-140 kDa). Both bands were endonuclease H sensitive, indicating immature glycosylation and failure of the protein to traffic out of the endoplasmic reticulum to the plasma membrane. Further phenotypic findings in the family included macroorchidism and infertility in the uncle and mild neurological phenotypes in the affected males, such as hypotonia, delayed psychomotor development, clumsy behavior, and attention deficit disorder., Conclusions: We identified a novel insertion mutation in the IGSF1 gene and further delineated the phenotype of the IGSF1-deficiency syndrome. Our findings indicate a possible association between an IGSF1 mutation and neurological phenotypes.
- Published
- 2016
- Full Text
- View/download PDF
44. Immunity, Life and Dancing Starlings: A Physician's Perspective.
- Author
-
Bercovich D, Goodman G, and Gershwin ME
- Subjects
- Animals, Birds, Humans, Physicians, Immunity, Life, Origin of Life
- Abstract
Background: Immune function is the most basic physiological process in humans and indeed throughout the animal kingdom. Interestingly, the vast majority of textbooks of physiology do not include a chapter on immunity. Our species survival is dependent on the diversity of the immune response and the ability for antigen presentation and effector mechanisms to be enormously promiscuous. As physicians, we are likely all too aware of how brief our life span is and the myriad of diseases and events that shorten it. It is not surprising that we question where our life comes from and our relationship within the universe. Many hypotheses have been offered regarding the likelihood that intelligent life exists elsewhere. We propose that such issues be discussed in the context of basic biologic observations on earth, such as the sight of a dense flock of tens of thousands of starlings maneuvering in rapid twists and turns at dusk before settling in trees for the night. The mathematical likelihood for life elsewhere was proposed by Frank Drake in a classic equation whose 'thesis' has stimulated the search for alien civilizations and the nature of life. A fundamental gap in this equation is the presence of a diverse immune response, a feature essential for survival of Life, presumably also extra-terrestrially.
- Published
- 2016
45. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
- Author
-
Baris HN, Barnes-Kedar I, Toledano H, Halpern M, Hershkovitz D, Lossos A, Lerer I, Peretz T, Kariv R, Cohen S, Half EE, Magal N, Drasinover V, Wimmer K, Goldberg Y, Bercovich D, and Levi Z
- Subjects
- Adolescent, Cafe-au-Lait Spots genetics, Child, Child, Preschool, Female, Humans, Immunohistochemistry, Israel, Lymphoma genetics, Male, Mismatch Repair Endonuclease PMS2, MutL Protein Homolog 1, Mutation, Pedigree, Young Adult, Adaptor Proteins, Signal Transducing genetics, Adenosine Triphosphatases genetics, Colorectal Neoplasms, Hereditary Nonpolyposis genetics, Consanguinity, DNA Mismatch Repair genetics, DNA Repair Enzymes genetics, DNA-Binding Proteins genetics, Founder Effect, MutS Homolog 2 Protein genetics, Nuclear Proteins genetics
- Abstract
Background: Heterozygous germline mutations in any of the mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and PMS2, cause Lynch syndrome (LS), an autosomal dominant cancer predisposition syndrome conferring a high risk of colorectal, endometrial, and other cancers in adulthood. Offspring of couples where both spouses have LS have a 1:4 risk of inheriting biallelic MMR gene mutations. These cause constitutional MMR deficiency (CMMRD) syndrome, a severe recessively inherited cancer syndrome with a broad tumor spectrum including mainly hematological malignancies, brain tumors, and colon cancer in childhood and adolescence. Many CMMRD children also present with café au lait spots and axillary freckling mimicking neurofibromatosis type 1., Procedure: We describe our experience in seven CMMRD families demonstrating the role and importance of founder mutations and consanguinity on its prevalence. Clinical presentations included brain tumors, colon cancer, lymphoma, and small bowel cancer., Results: In children from two nonconsanguineous Ashkenazi Jewish (AJ) families, the common Ashkenazi founder mutations were detected; these were homozygous in one family and compound heterozygous in the other. In four consanguineous families of various ancestries, different homozygous mutations were identified. In a nonconsanguineous Caucasus/AJ family, lack of PMS2 was demonstrated in tumor and normal tissues; however, mutations were not identified., Conclusions: CMMRD is rare, but, especially in areas where founder mutations for LS and consanguinity are common, pediatricians should be aware of it since they are the first to encounter these children. Early diagnosis will enable tailored cancer surveillance in the entire family and a discussion regarding prenatal genetic diagnosis., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
46. Increased risk for colorectal adenomas and cancer in mono-allelic MUTYH mutation carriers: results from a cohort of North-African Jews.
- Author
-
Rosner G, Bercovich D, Daniel YE, Strul H, Fliss-Isakov N, Ben-Yehoiada M, Santo E, Halpern Z, and Kariv R
- Subjects
- Adenomatous Polyps genetics, Adult, Africa, Northern ethnology, Aged, Alleles, Case-Control Studies, Cohort Studies, Female, Genetic Predisposition to Disease, Heterozygote, Humans, Israel ethnology, Jews genetics, Male, Middle Aged, Adenoma genetics, Colorectal Neoplasms genetics, DNA Glycosylases genetics, Mutation
- Abstract
Bi-allelic MUTYH gene mutations are associated with a clinical phenotype of multiple colorectal adenomas and an increased risk for colorectal cancer (CRC). It is unclear whether mono-allelic MUTYH gene carriers (heterozygotes) are also at increased risk for even few adenomas or cancer. In order to clarify an association between MUTYH heterozygotes and adenomas, we evaluated the frequency and types of MUTYH mutations and variants in 72 North-African Jews having few (≥3) colorectal adenomas with or without early onset (<50 years) CRC compared to 29 healthy controls. Germ-line DNA was analyzed for a panel of 6 MUTYH mutations and variants, and Sanger sequencing of the entire MUTYH gene was performed for mono-allelic MUTYH mutation carriers. APC gene mutations and Lynch syndrome were excluded in the relevant cases according to accepted clinical criteria. Twenty-two of the 72 adenoma subjects (30.5%) had MUTYH mutations or variants. Nine were homozygotes or compound heterozygotes: all had >10 adenomas and one had CRC. Thirteen others were mono-allelic carriers (heterozygotes) of a single MUTYH mutation: six had more than ten adenomas and seven had less than ten adenomas; of these 13 mono-allelic carriers, six had a neoplasm: three CRCs and three extra-intestinal tumors. Eleven of the thirteen mono-allelic carriers with adenomas had a family history of cancer in first or second degree relatives. A multivariable model showed positive correlation between G396D, Y179C and 1186 ins GG mutations and number of adenomas (OR 8.6, 10.2 and 14.4, respectively). The Q324H variant was negatively associated with the number of adenomatous polyps (OR -5.23). In conclusion, MUTYH mutations are prevalent among Jews of North-African origin with colorectal adenomas with or without early onset CRC. Mono-allelic MUTYH carriers with a family history of cancer had a clinical phenotype that varied from having only few adenomas to multiple (>10) adenomas. These findings support MUTYH testing in patients with even few adenomas and suggest the consideration of increased surveillance in mono-allelic carriers with a family history of cancer.
- Published
- 2015
- Full Text
- View/download PDF
47. Minichromosome maintenance complex component 8 (MCM8) gene mutations result in primary gonadal failure.
- Author
-
Tenenbaum-Rakover Y, Weinberg-Shukron A, Renbaum P, Lobel O, Eideh H, Gulsuner S, Dahary D, Abu-Rayyan A, Kanaan M, Levy-Lahad E, Bercovich D, and Zangen D
- Subjects
- Adolescent, Alleles, Chromosomal Instability, Chromosome Breakage, Chromosome Mapping, Consanguinity, DNA Copy Number Variations, DNA, Complementary genetics, Exome, Female, Gene Expression, Genetic Association Studies, Genome-Wide Association Study, Gonadal Disorders diagnosis, High-Throughput Nucleotide Sequencing, Homozygote, Humans, Infant, Newborn, Male, Ovary metabolism, Pedigree, Polymorphism, Single Nucleotide, RNA Splice Sites, RNA, Messenger genetics, Siblings, Gonadal Disorders genetics, Minichromosome Maintenance Complex Component 8 genetics, Mutation
- Abstract
Background: Primary gonadal failure is characterised by primary amenorrhoea or early menopause in females, and oligospermia or azoospermia in males. Variants of the minichromosome maintenance complex component 8 gene (MCM8) have recently been shown to be significantly associated with women's menopausal age in genome-wide association studies. Furthermore, MCM8-knockout mice are sterile. The objective of this study was to elucidate the genetic aetiology of gonadal failure in two consanguineous families presenting as primary amenorrhoea in the females and as small testes and azoospermia in a male., Methods and Results: Using whole exome sequencing, we identified two novel homozygous mutations in the MCM8 gene: a splice (c.1954-1G>A) and a frameshift (c.1469-1470insTA). In each consanguineous family the mutation segregated with the disease and both mutations were absent in 100 ethnically matched controls. The splice mutation led to lack of the wild-type transcript and three different aberrant transcripts predicted to result in either truncated or significantly shorter proteins. Quantitative analysis of the aberrantly spliced transcripts showed a significant decrease in total MCM8 message in affected homozygotes for the mutation, and an intermediate decrease in heterozygous family members. Chromosomal breakage following exposure to mitomcyin C was significantly increased in cells from homozygous individuals for c.1954-1G>A, as well as c.1469-1470insTA., Conclusions: MCM8, a component of the pre-replication complex, is crucial for gonadal development and maintenance in humans-both males and females. These findings provide new insights into the genetic disorders of infertility and premature menopause in women., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF
48. Long-term outcome of loss-of-function mutations in thyrotropin receptor gene.
- Author
-
Tenenbaum-Rakover Y, Almashanu S, Hess O, Admoni O, Hag-Dahood Mahameed A, Schwartz N, Allon-Shalev S, Bercovich D, and Refetoff S
- Subjects
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Heterozygote, Homozygote, Humans, Infant, Infant, Newborn, Male, Neonatal Screening, Thyroid Function Tests, Thyroid Gland physiopathology, Thyrotropin metabolism, Treatment Outcome, Young Adult, Congenital Hypothyroidism genetics, Hypothyroidism genetics, Mutation, Receptors, Thyrotropin genetics
- Abstract
Background: Loss-of-function mutations in the thyrotropin receptor (TSHR) gene lead to resistance to TSH (RTSH) presenting with either congenital hypothyroidism (CH) or subclinical hypothyroidism (SCH). Despite several reports of patients with TSHR mutations, data on the long-term outcome of this condition are limited, and no consensus exists on the need for hormone replacement therapy. The aim of the present study was to assess the long-term outcome in children and adolescents with RTSH due to TSHR mutations., Methods: The TSHR gene was sequenced in 94 subjects (aged 3 days-21 years) with either nonautoimmune SCH or CH with RTSH., Results: Twenty-seven subjects (29%) carried mutations in TSHR. Fifteen infants were identified by neonatal screening, and the other 79 patients were detected in the process of testing for various other conditions or because of family occurrence of thyroid test abnormalities. Six different mutations were identified: c.484C>G (p.P162A), c.202C>T (p.P68S), c.790C>T (p.P264S), c.269A>C (p.Q90P), c.1957C>G (p.L653V), and c.1347C>T (p.R450C). Twelve subjects were homozygous, three were compound heterozygous, and 12 were heterozygous. Mean serum TSH levels at diagnosis and at last visit were significantly higher in patients with TSHR mutations than in those without mutations (29.04 vs. 14.15, p=0.002; 31.73 vs. 6.19, p<0.0001, respectively). Homozygous patients had a more severe phenotype (TSH 53.6 vs. 9.24, p<0.0001). Mean serum free thyroxine (fT4) levels at the last visit were significantly lower than at the first visit in the homozygous individuals (p=0.05) for a follow-up period of as long as 11 years. Heterozygous subjects had only mild hyperthyrotropinemia with stable TSH levels. However, homozygous subjects showed a trend toward increased TSH and decreased fT4 with time., Conclusion: SCH in heterozygotes with TSHR mutations is a stable compensated condition with an appropriately adjusted set point for pituitary-thyroid feedback that does not require replacement therapy. However, homozygous subjects, with incompletely compensated SCH, show reduced fT4 levels over time and may require levothyroxine treatment. Replacement therapy should be considered on an individual basis, and long-term follow up is recommended.
- Published
- 2015
- Full Text
- View/download PDF
49. Dispersal of an ancient retroposon in the TP53 promoter of Bovidae: phylogeny, novel mechanisms, and potential implications for cow milk persistency.
- Author
-
Dekel Y, Machluf Y, Ben-Dor S, Yifa O, Stoler A, Ben-Shlomo I, and Bercovich D
- Subjects
- Animals, Buffaloes genetics, Cattle, Female, Gene Regulatory Networks genetics, Genome, Milk, Molecular Sequence Data, STAT3 Transcription Factor genetics, Evolution, Molecular, Phylogeny, Short Interspersed Nucleotide Elements genetics, Tumor Suppressor Protein p53 genetics
- Abstract
Background: In recent years, the perception of transposable genetic elements has changed from "junk DNA" to a focus of interest when appearing near or inside genes. Bov-A2 is a short interspersed nuclear element (SINE) that was first found in Bovidae and later in other ruminants. This retroposon is mostly used as a marker for phylogenetic analysis., Results: We describe insertions of Bov-A2 in the promoter region of TP53, a key tumor suppressor gene that is indispensable for diverse developmental processes, in Antilopinae and Tragelaphini (belonging to the Bovinae subfamily). In Tragelaphini two Bov-A2 elements were inserted sequentially, whereas in 5 tribes of Antilopinae only one Bov-A2 element was inserted, in a different site and reverse orientation. The entrance site in both cases employed short palindromes that can form hairpin secondary structures. Interestingly, mutations that create or disrupt base pairing in the palindrome sequence dictated the presence or absence of Bov-A2, such as in the domestic cow and buffalo, which lack Bov-A2. Transcription factor binding site analysis revealed unique binding sites for STAT3 and NFκB within the Bov-A2 sequence, which together with TP53 itself are known to play a crucial role in mammary involution., Conclusions: This report demonstrates how short palindromes serve as hot spots for Bov-A2 retroposon insertion into the mammalian genome. The strict correlation between point mutation in the palindromes and the presence/absence of Bov-A2 retroposon insertions, questions the use of singular insertion events as valid phylogenetic markers inside families. Bov-A2 insertion into the TP53 promoter in Antilopinae and Tragelaphini may not only provide a genetic network that regulates mammary involution, but can also answer the need for rapid mammary involution in Savanna antelopes after weaning, partially in response to predation stress. The absence of Bov-A2 in domestic bovids may constitute the molecular background for greater lactation persistency.
- Published
- 2015
- Full Text
- View/download PDF
50. Mars can wait: facing the challenges of our civilization.
- Author
-
Goodman G, Gershwin ME, and Bercovich D
- Subjects
- Biomedical Research, Civilization, Environment, Humans, Brain anatomy & histology, Brain physiology, Electromagnetic Phenomena, Life, Models, Neurological
- Abstract
We are overwhelmed by warnings about inevitable geophysical and human problems. Earth is beset by escalating, manmade, environmental crises and our exploding population will eventually lack water, food and vital materials. This suggests, together with increasing poverty, deepening social unrest and advanced techniques for mass killing, that civilization will break down long before atmospheric CO2 or resistant microbes become catastrophic. Despite intensive searching, life has not been found in space, even though thousands of planets have been found and life there may be as problematic and unpredictable as on Earth. The human brain is already a 'universe', with 85 billion neurons and a hundred trillion synapses, more than the stars in our galaxy. Understanding consciousness, the brain, its aging and pathologies, and eliminating the propensity for human aggression are urgent challenges. During 1958-2012, NASA spent $800 billion. In contrast, the annual cost of brain disease in the U.S. is $600 billion, more than cardiovascular disease and cancer combined. We suggest that a massive switching of financial and human resources is required to explore the full potential of the human brain. Visiting Mars can wait. We further propose a novel Two-Brain Hypothesis: the animal 'brain' evolved as two fundamentally different though interdependent, complementary organs: one electroionic (tangible, known and accessible), and the other, electromagnetic (intangible and difficult to access)--a relatively independent, stable, structured and functional 3D compendium of variously induced interacting EM fields.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.